About: Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening
Creator	Ch, Eberhardt@unige, Christiane Jn, Eberhardt Np, Breuckmann
source	Elsevier; Medline; PMC
abstract	Abstract Background SARS-CoV-2 test kits are in critical shortage in many countries. This limits large-scale population testing and hinders the effort to identify and isolate infected individuals. Objective Herein, we developed and evaluated multi-stage group testing schemes that test samples in groups of various pool sizes in multiple stages. Through this approach, groups of negative samples can be eliminated with a single test, avoiding the need for individual testing and achieving considerable savings of resources. Study design We designed and parameterized various multi-stage testing schemes and compared their efficiency at different prevalence rates using computer simulations. Results We found that three-stage testing schemes with pool sizes of maximum 16 samples can test up to three and seven times as many individuals with the same number of test kits for prevalence rates of around 5% and 1%, respectively. We propose an adaptive approach, where the optimal testing scheme is selected based on the expected prevalence rate. Conclusion These group testing schemes could lead to a major reduction in the number of testing kits required and help improve large-scale population testing in general and in the context of the current COVID-19 pandemic.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104382
bibo:pmid	32388468
has license	els-covid
sha1sum (hex)	f3c4398f6b45ab207d73f7f7eeafc22078180b67
schema:url	https://doi.org/10.1016/j.jcv.2020.104382
resource representing a document's title	Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening
has PubMed Central identifier	PMC7177109
has PubMed identifier	32388468
schema:publication	J Clin Virol
resource representing a document's body	covid:f3c4398f6b45ab207d73f7f7eeafc22078180b67#body_text
is schema:about of	named entity 'COVID-19' named entity 'COVID-19' named entity 'Group Testing' named entity '7.2' named entity 'Germany' named entity 'infection' named entity 'PCR testing' named entity 'PCR testing' named entity 'prevalence rate' named entity 'SARS-CoV-2' named entity 'viral load' named entity '7.1' named entity 'positive or negative' named entity 'public health' named entity 'PCR testing' named entity 'COVID-19 pandemic' named entity 'Germany' named entity 'test kits' named entity 'prevalence rate' named entity 'group testing' named entity 'test sensitivity' named entity 'group testing' named entity 'statistical method' named entity 'healthcare workers' named entity 'risk factors' named entity 'prevalence rate' named entity 'test kits' named entity 'PCR testing' named entity 'prevalence rate' named entity 'PCR' named entity '3.8' named entity 'Group testing' named entity 'epitope mapping' named entity 'group testing' named entity 'MATPLOTLIB' named entity 'group testing' named entity 'prevalence rate' named entity 'maximum pool' named entity 'antibody testing' named entity 'SARS-Cov-2' named entity 'tested positive' named entity '3.8' named entity 'SARS-Cov-2' named entity 'prevalence rate' named entity 'human error' named entity 'prevalence rate' named entity 'prevalence rate' named entity 'prevalence rate' named entity 'group testing' named entity 'group testing' named entity 'factor 8' named entity 'SARS-CoV-2' named entity 'group testing' named entity 'severe diseases' named entity 'prevalence rate' named entity 'infection' named entity 'SARS-CoV-2' named entity '7.1' named entity 'prevalence rate' named entity 'tested positive' named entity 'COVID-19' named entity 'group testing' named entity 'HIV screening' named entity 'serum samples' named entity 'syphilis' named entity 'U.S.' named entity 'group testing' named entity 'maximum pool' named entity 'group testing' named entity 'SARS-CoV-2' named entity 'prevalence rate' named entity 'group testing' named entity 'group testing' named entity 'prevalence rate' named entity 'group testing' named entity 'anti-HIV' named entity 'MATPLOTLIB' named entity 'group testing'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software